{"product_id":"biolegend-317408","title":"Biolegend, 317408, FITC anti-human CD4 Antibody, 100tests","description":"\u003cp\u003eCD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes\/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16.\u003cbr\u003e\n100tests\u003cbr\u003e\nVerified Reactivity: Human, Cynomolgus, Rhesus\u003cbr\u003e\nReported Reactivity: Chimpanzee\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Mouse\u003cbr\u003e\nImmunogen: Human peripheral T cells\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.\u003cbr\u003e\nConcentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)\u003cbr\u003e\nStorage \u0026amp; Handling: The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: FC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.\u003cbr\u003e\nExcitation Laser: Blue Laser (488 nm)\u003cbr\u003e\nApplication Notes: The OKT4 antibody binds to the D3 domain of CD4 and does not block HIV binding. Additional reported applications (for the relevant formats) include: immunohistochemistry of frozen sections and blocking of T cell activation. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin \u0026lt; 0.01 EU\/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317453 and 317454). In a small subset of individuals, the OKT4 clone does not bind to CD4 due to polymorphisms in CD4.9\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. 76:4061. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed Cicin-Sain L, et al. 2010. J. Immunol. 184:6739. PubMed Rosenzweig M, et al. 2001. J. Med. Primatol. 30:36. Linder J, et al. 1987. Am. J. Pathol. 127:1. Boche D, et al. 1999. J. Neurovirol. 5:232. (IHC) Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. USA. 76:4061. (Immunogen) Lederman S, et al. 1991. Mol Immunol. 28:1171-81.\u003cbr\u003e\nProduct Citations: Varkey R, et al. 2019. PLoS One. 14:e0211236. PubMed Yang M, et al. 2019. Cell Physiol Biochem. 52:1178. PubMed Sasaki E, et al. 2018. J Immunotoxicol. 15:53. PubMed Xiao C, et al. 2023. Nat Aging. 3:418. PubMed Gan X, et al. 2022. Proc Natl Acad Sci U S A. 119:e2200879119. PubMed Zhang B, et al. 2023. Signal Transduct Target Ther. 8:28. PubMed Rosain J, et al. 2023. Cell. 186:621. PubMed Riaz T, et al. 2016. Mol Cell Proteomics. 15: 1007 - 1016. PubMed Trzupek D, et al. 2022. Wellcome Open Res. 6:149. PubMed Andonian BJ, et al. 2022. Sci Rep. 12:7450. PubMed Kieffer T, et al. 2017. J Reprod Immunol. 10.1016\/j.jri.2016.11.004. PubMed Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed Zhao Y, et al. 2021. Front Immunol. 12:665442. PubMed Rodriguez-García A, et al. 2020. Mol Ther. 28:548. PubMed Enghard P, et al. 2014. Ann Rheum Dis. 73:277. PubMed Hixon JA, et al. 2020. Leukemia. 34:35. PubMed Pan YG, et al. 2021. Immunity. 54(6):1245-1256.e5. PubMed Zhou Y, et al. 2017. Front Cell Infect Microbiol. 7:457. PubMed Gorczynski RM, et al. 2017. Immunology. 150:418. PubMed Meng S, et al. 2018. Mol Med Rep. 18:4247. PubMed Buchan SL et al. 2018. Immunity. 49(5):958-970 . PubMed Zhang T, et al. 2012. J Immunol. 189:2290. PubMed Narsale A, Moya R, Robertson H 2016. Data Brief. 8: 1348-51. PubMed Chen Y, et al. 2021. Transl Lung Cancer Res. 10:2193. PubMed Zhang J, et al. 2022. Nature. 609:369. PubMed Kashima Y, et al. 2022. Life Sci Alliance. 5:. PubMed Cai J, et al. 2021. eLife. 10:00. PubMed Liu J, et al. 2021. Medicine (Baltimore). 100:e24619. PubMed Kilpelainen A, et al. 2022. Front Immunol. 13:815041. PubMed Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed Del Alcazar D, et al. 2019. Cell Rep. 28:3047. PubMed Du Q, et al. 2018. J Immunol. 201:533. PubMed Yang B, et al. 2015. Cell Immunol. Available online 12 August 2015. PubMed Gao X, et al. 2022. iScience. 25:104911. PubMed Leclercq G, et al. 2022. J Immunother Cancer. 10:. PubMed Bending D, et al. 2015. J Immunol. 195: 5616 - 5624. PubMed Verma K, et al. 2017. PLoS One.. 10.1371\/journal.pone.0183828. PubMed Saraiva DP, et al. 2018. Front Immunol. 2.184027778. PubMed Teni Nurlatifah HR, et al. 2021. Med Arch. 75:335. PubMed Tong L, et al. 2021. Front Microbiol. 12:704449. PubMed Comte D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9321 - 9326. PubMed Yang YK, et al. 2021. Stem Cell Res Ther. 12:156. PubMed Barresi V, et al. 2020. J Clin Med. 9:00. PubMed Hr TN, et al. 2021. Allergol Immunopathol (Madr). 49:193. PubMed Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed Loo Yau H, et al. 2021. STAR Protocols. 2(2):100549. PubMed Wang L, et al. 2018. Oncol Lett. 15:8635. PubMed Zhu P, et al. 2022. Cell Commun Signal. 20:121. PubMed Hebbandi Nanjundappa R, et al. 2017. Cell. 171:655. PubMed Jiang J, et al. 2016. Sci Rep. 6: 32320. PubMed Hui Z, et al. 2022. Cell Death Dis. 13:607. PubMed\u003cbr\u003e\nRRID: AB_571950 (BioLegend Cat. No. 317407) AB_571951 (BioLegend Cat. No. 317408)\u003cbr\u003e\nStructure: Ig superfamily, type I transmembrane glycoprotein, 55 kD\u003cbr\u003e\nDistribution: T cell subset, majority of thymocytes, monocytes\/macrophages\u003cbr\u003e\nFunction: MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor\u003cbr\u003e\nLigand\/Receptor: MHC class II molecules, HIV gp120, IL-16\u003cbr\u003e\nCell Type: Macrophages, Monocytes, T cells, Thymocytes, Tregs\u003cbr\u003e\nBiology Area: Immunology\u003cbr\u003e\nMolecular Family: CD Molecules\u003cbr\u003e\nAntigen References: 1. Center D, et al. 1996. Immunol. Today 17:476. 2. Gaubin M, et al. 1996. Eur. J. Clin. Chem. Clin. Biochem. 34:723.\u003cbr\u003e\nGene ID: 920\u003cbr\u003e\nUniProt: View information about CD4 on UniProt.org\u003cbr\u003e\nClone: OKT4\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nWorkshop: HCDM listed\u003cbr\u003e\nOther Names: T4\u003cbr\u003e\nIsotype: Mouse IgG2b, κ\u003cbr\u003e\nQ: I am unable to see expression of T cell markers such as CD3 and CD4 post activation.\u003cbr\u003e\nA: TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA\/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46866159206569,"sku":"317408","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/biolegend-317408","provider":"Iright","version":"1.0","type":"link"}